TY - JOUR
T1 - Bevacizumab combined with gemcitabine and capecitabine for advanced pancreatic cancer
T2 - A phase II study
AU - Javle, M.
AU - Yu, J.
AU - Garrett, C.
AU - Pande, A.
AU - Kuvshinoff, B.
AU - Litwin, A.
AU - Phelan, J.
AU - Gibbs, J.
AU - Iyer, R.
PY - 2009/6/16
Y1 - 2009/6/16
N2 - A total of 50 patients with advanced pancreatic cancer were enrolled in a phase II study of bevacizumab 15mgkg1, capecitabine 1300mgm 2 daily for 2 weeks and gemcitabine 1000mgm2 weekly 2 times; cycles were repeated every 21 days. Radiological response rate was 22; progression-free survival and over survival were 5.8 and 9.8 months respectively. Grade 3 or 4 toxicities included neutropaenia (22), thrombocytopaenia (14), thromboembolic events (12), hypertension (8) and haemorrhage (6).
AB - A total of 50 patients with advanced pancreatic cancer were enrolled in a phase II study of bevacizumab 15mgkg1, capecitabine 1300mgm 2 daily for 2 weeks and gemcitabine 1000mgm2 weekly 2 times; cycles were repeated every 21 days. Radiological response rate was 22; progression-free survival and over survival were 5.8 and 9.8 months respectively. Grade 3 or 4 toxicities included neutropaenia (22), thrombocytopaenia (14), thromboembolic events (12), hypertension (8) and haemorrhage (6).
UR - http://www.scopus.com/inward/record.url?scp=67349250514&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=67349250514&partnerID=8YFLogxK
U2 - 10.1038/sj.bjc.6605099
DO - 10.1038/sj.bjc.6605099
M3 - Article
C2 - 19491904
AN - SCOPUS:67349250514
SN - 0007-0920
VL - 100
SP - 1842
EP - 1845
JO - British Journal of Cancer
JF - British Journal of Cancer
IS - 12
ER -